These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 29171377)
1. [Off-label prescription of antipsychotics]. Boot E Ned Tijdschr Geneeskd; 2017; 161():D2035. PubMed ID: 29171377 [TBL] [Abstract][Full Text] [Related]
2. Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability. de Kuijper GM; Hoekstra PJ J Intellect Disabil Res; 2017 Oct; 61(10):899-908. PubMed ID: 28560761 [TBL] [Abstract][Full Text] [Related]
3. An Open-Label Discontinuation Trial of Long-Term, Off-Label Antipsychotic Medication in People With Intellectual Disability: Determinants of Success and Failure. de Kuijper GM; Hoekstra PJ J Clin Pharmacol; 2018 Nov; 58(11):1418-1426. PubMed ID: 29920689 [TBL] [Abstract][Full Text] [Related]
4. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. de Kuijper G; Evenhuis H; Minderaa RB; Hoekstra PJ J Intellect Disabil Res; 2014 Jan; 58(1):71-83. PubMed ID: 23046144 [TBL] [Abstract][Full Text] [Related]
5. An open label discontinuation trial of long-term used off-label antipsychotic drugs in people with intellectual disability: The influence of staff-related factors. de Kuijper GM; Hoekstra PJ J Appl Res Intellect Disabil; 2019 Mar; 32(2):313-322. PubMed ID: 30264420 [TBL] [Abstract][Full Text] [Related]
6. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. Deb S; Unwin G; Deb T J Intellect Disabil Res; 2015 Jan; 59(1):11-25. PubMed ID: 24450426 [TBL] [Abstract][Full Text] [Related]
7. Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review. Sheehan R; Hassiotis A Lancet Psychiatry; 2017 Mar; 4(3):238-256. PubMed ID: 27838214 [TBL] [Abstract][Full Text] [Related]
8. Safety of antipsychotics in people with intellectual disability. Frighi V; Stephenson MT; Morovat A; Jolley IE; Trivella M; Dudley CA; Anand E; White SJ; Hammond CV; Hockney RA; Barrow B; Shakir R; Goodwin GM Br J Psychiatry; 2011 Oct; 199(4):289-95. PubMed ID: 21816867 [TBL] [Abstract][Full Text] [Related]
9. Study on the use of Antipsychotic Medication in an Intellectual Disability (ID) community caseload. Thalitaya MD; Reynolds C; Ismail I Psychiatr Danub; 2017 Sep; 29(Suppl 3):578-583. PubMed ID: 28953833 [TBL] [Abstract][Full Text] [Related]
10. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. de Kuijper G; Mulder H; Evenhuis H; Visser F; Hoekstra PJ J Clin Psychopharmacol; 2013 Aug; 33(4):520-4. PubMed ID: 23775048 [TBL] [Abstract][Full Text] [Related]
11. Incident users of antipsychotics: who are they and how do they fare? Baandrup L; Kruse M Soc Psychiatry Psychiatr Epidemiol; 2016 Apr; 51(4):505-12. PubMed ID: 26409887 [TBL] [Abstract][Full Text] [Related]
12. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Leslie DL; Mohamed S; Rosenheck RA Psychiatr Serv; 2009 Sep; 60(9):1175-81. PubMed ID: 19723731 [TBL] [Abstract][Full Text] [Related]
13. Demographic and diagnostic profiles of older people with intellectual disability and prescription of antipsychotics. Axmon A; Ahlström G; Gagnemo Persson R; Eberhard J Soc Psychiatry Psychiatr Epidemiol; 2019 Aug; 54(8):937-944. PubMed ID: 30903237 [TBL] [Abstract][Full Text] [Related]
14. Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey. Perry BI; Cooray SE; Mendis J; Purandare K; Wijeratne A; Manjubhashini S; Dasari M; Esan F; Gunaratna I; Naseem RA; Hoare S; Chester V; Roy A; Devapriam J; Alexander R; Kwok HF J Intellect Disabil Res; 2018 Feb; 62(2):140-149. PubMed ID: 29349928 [TBL] [Abstract][Full Text] [Related]
15. Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics. de Kuijper G; Mulder H; Evenhuis H; Scholte F; Visser F; Hoekstra PJ Res Dev Disabil; 2013 Sep; 34(9):2799-809. PubMed ID: 23792429 [TBL] [Abstract][Full Text] [Related]
16. Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial. Beumer S; Hamers P; Oppewal A; Maes-Festen D BMC Psychiatry; 2021 Sep; 21(1):439. PubMed ID: 34488701 [TBL] [Abstract][Full Text] [Related]
17. Off-label second generation antipsychotics for impulse regulation disorders: a review. Scheltema Beduin A; de Haan L Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846 [TBL] [Abstract][Full Text] [Related]
18. Withdrawing Antipsychotics for Challenging Behaviours in Adults with Intellectual Disabilities: Experiences and Views of Experts by Experience. de Kuijper G; de Haan J; Deb S; Shankar R Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497711 [TBL] [Abstract][Full Text] [Related]
19. Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics. Montebello ME; Brett J Curr Top Behav Neurosci; 2017; 34():125-139. PubMed ID: 26695164 [TBL] [Abstract][Full Text] [Related]
20. Trends in Off-Label Use of Second-Generation Antipsychotics in the Medicare Population From 2006 to 2012. Driessen J; Baik SH; Zhang Y Psychiatr Serv; 2016 Aug; 67(8):898-903. PubMed ID: 27079991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]